Current phase of treatment-Induction Treatment Posts on Medivizor
Navigation Menu

Current phase of treatment-Induction Treatment Posts on Medivizor

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva).  This study concluded that this treatment is effective and does not impair the quality of life in these...

Read More

Combining all-trans-retinoic acid, arsenic trioxide and idarubicin for the treatment of acute promyelocytic leukemia 

Combining all-trans-retinoic acid, arsenic trioxide and idarubicin for the treatment of acute promyelocytic leukemia 

Posted by on Jul 11, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the combination of all-trans-retinoic acid (Vesanoid), arsenic trioxide (Trisenox), and idarubicin (Idamycin) as front-line treatment for acute promyelocytic leukemia.  This study concluded that this combination is safe and effective for these...

Read More

Long-term outcomes for acute myeloid leukemia patients treated with reduced intensity conditioning and hematopoietic stem cell transplant

Posted by on Apr 10, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term outcomes for patients with acute myeloid leukemia who received reduced-intensity conditioning and allogeneic stem cell transplant.  This study concluded that this treatment is safe and effective in these patients in the long-term.   Some background One of the standard...

Read More

What major factors affect disease progression and outcome in adults with acute myeloid leukemia?

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...

Read More

Is there a link between recovery time for healthy white blood cells and infections in children with AML?

Posted by on Jul 15, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of neutrophil recovery time (NRT – the return of white blood cells after treatment, that fight infection) on infections and relapse (return of disease) in children with acute myeloid leukaemia (AML). The study found that longer NRT was linked with increased risk of severe infections and relapse after...

Read More

Consolidation treatment with lenalidomide may improve response in patients with residual disease after treatment

Posted by on Oct 25, 2017 in Leukemia | 0 comments

In a nutshell This study examined lenalidomide (Revlimid) as a consolidation strategy in patients with chronic lymphocytic leukemia (CLL) who have residual disease after treatment. This study reported good response improvements (in 45% of patients with residual disease). Lenalidomide may be particularly suited as a consolidation strategy after...

Read More

Daunorubicin dose in AML

Posted by on Mar 16, 2017 in Leukemia | 0 comments

In a nutshell This study, from 2009, examined the effectiveness of increasing the dose of daunorubicin (Cerubidine) in acute myeloid leukemia (AML). This study concluded that a higher dose improved remission rates (no sign of disease) and 2-year survival rates. Some background The standard induction therapy (treatment to induce remission) for AML...

Read More